A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

These findings identify MEK/ERK as a new signaling pathway activated by NPM/ALK and indicate that the pathway represents a novel therapeutic target in the ALK-induced malignancies. Here we report ...

If validated, the use of anaplastic lymphoma kinase (ALK) inhibitors may be a new treatment ... tumor cell lines and animal models to evaluate protein-signaling pathways and genetic abnormalities ...

It has been shown that downstream effectors of ALK tyrosine kinase activity include the Ras-ERK, PI 3-K-Akt, JAK-STAT, and NF-κB signaling pathways. In the absence of ligand binding, several ALK ...

Looking for connections, the team used cell lines derived from patients’ tumors and individually examined several signaling molecules potentially triggered by the ALK mutation. These included pathways ...

The sustained selective pressure of the drug leads to resistance-promoting changes in the ALK protein itself, but also changes in other cell signaling pathways can lead to insensitivity to ALK ...

Receptors such as EGFR, HER2, MET and ALK interface with common downstream signaling pathways and 'addiction switching' can occur, either by the inhibition of one receptor triggering a switch to ...

A. Outline of GeCKO screening using organoids. Gastric organoids are established from mice that allow visualization of tissue stem cells; genes are randomly rendered loss-of-function by ...

In cell lines directly generated from patients with anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers ... bypass resistance mutations ultimately converged on the same signaling ...